Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 12:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 70 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Post-Herpetic Neuralgia (PHN) Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Shingles Prevention Study

NCT00007501
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
Varicella-zoster vaccine, Placebo
Biological
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years and older
Enrollment
38,456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2013 · Synced Oct 8, 2026, 12:03 PM EDT
Not listed Phase 2 Interventional

Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia

NCT00099528
View directory record Official record
Conditions
Neuralgia, Shingles, Peripheral Nervous System Disease
Interventions
REN-1654
Drug
Lead sponsor
Renovis
Industry
Eligibility
55 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2010 · Synced Oct 8, 2026, 12:03 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

NCT00636636
View directory record Official record
Conditions
Neuralgia,Postherpetic
Interventions
Gabapentin Extended Release tablets, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
36
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 8, 2026, 12:03 PM EDT
Completed Phase 3 Interventional Results available

Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

NCT00415597
View directory record Official record
Conditions
Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 8, 2026, 12:03 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Z160 in Subjects With Postherpetic Neuralgia

NCT01757873
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Z160, Placebo
Drug
Lead sponsor
Zalicus
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
53
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Oct 8, 2026, 12:03 PM EDT
Not listed No phase listed Observational

Development of a Bedside Pain Assessment Kit for Postherpetic Neuralgia

NCT01166295
View directory record Official record
Conditions
Neuralgia, Herpes Zoster
Interventions
Not listed
Lead sponsor
Analgesic Solutions
Industry
Eligibility
40 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2010 · Synced Oct 8, 2026, 12:03 PM EDT
Not listed Phase 2 Interventional

Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia

NCT00813826
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
SLC022, Placebo
Drug
Lead sponsor
Solace Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Sierra Vista, Arizona • Mission Viejo, California • Orlando, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2009 · Synced Oct 8, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia

NCT04662281
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Placebo, LX9211
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Scottsdale, Arizona • Tucson, Arizona • Greenbrae, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 8, 2026, 12:03 PM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

NCT01058642
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
ADL5747, Placebo, Pregabalin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 8, 2026, 12:03 PM EDT
Completed Not applicable Interventional Results available

Effects of Pennsaid on Clinical Neuropathic Pain

NCT01508676
View directory record Official record
Conditions
Neuralgia, Postherpetic Neuralgia, Reflex Sympathetic Dystrophy, Complex Regional Pain Syndrome (CRPS)
Interventions
Pennsaid, Placebo (2.3% DMSO solution)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 8, 2026, 12:03 PM EDT
Not listed Phase 2 Interventional

Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)

NCT00652184
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
ARYS-01 (sorivudine) cream 3% or placebo cream, placebo, valaciclovir
Drug
Lead sponsor
aRigen Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Beverly Hills, California • Encino, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2008 · Synced Oct 8, 2026, 12:03 PM EDT
Terminated Phase 2 Interventional Results available

Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve

NCT01886313
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Civamide Nasal Spray, Placebo
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
21 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Santa Monica, California • Lauderdale Lakes, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 8, 2026, 12:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

New Topical Treatment for Continued Pain After Shingles

NCT00566904
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Epikeia coatings with aspirin, Epikeia coatings with lidocaine, Epikeia coatings alone
Drug · Other
Lead sponsor
Biomedical Development Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2011 · Synced Oct 8, 2026, 12:03 PM EDT
Completed Phase 2 Interventional

Crossover Post-herpetic Neuralgia (PHN)

NCT01305538
View directory record Official record
Conditions
Post-Herpetic Neuralgia (PHN)
Interventions
BMS-954561, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Phoenix, Arizona • Lomita, California • Boulder, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 8, 2026, 12:03 PM EDT
Completed Phase 2 Interventional

Study of NGX-1998 for the Treatment of Postherpetic Neuralgia

NCT01228838
View directory record Official record
Conditions
Postherpetic Neuralgia, Pain
Interventions
NGX-1998, Placebo Liquid
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years to 90 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
35
States / cities
Huntsville, Alabama • Tucson, Arizona • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 8, 2026, 12:03 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants

NCT07618715
View directory record Official record
Conditions
Healthy Male and Female Subjects
Interventions
Y-4 tablet, Pregabalin capsule, Riluzole tablet
Drug
Lead sponsor
Neurodawn Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 8, 2026, 12:03 PM EDT
Completed Phase 3 Interventional

Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

NCT00068081
View directory record Official record
Conditions
Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Oct 8, 2026, 12:03 PM EDT
Completed Phase 2 Interventional

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)

NCT01688947
View directory record Official record
Conditions
Postherpetic Neuralgia, Pain
Interventions
V116517 50-mg tablets, V116517 30-mg tablets, Pregabalin capsules, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
21 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
28
States / cities
Tucson, Arizona • La Jolla, California • North Hollywood, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 8, 2026, 12:03 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo

NCT00352651
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
Pregabalin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 8, 2026, 12:03 PM EDT
Terminated Phase 2 Interventional

A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.

NCT00353808
View directory record Official record
Conditions
Pain
Interventions
[S,S]-Reboxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
57
States / cities
Huntsville, Alabama • Chandler, Arizona • Gilbert, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2011 · Synced Oct 8, 2026, 12:03 PM EDT
Terminated Phase 2 Interventional

Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia

NCT00809679
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
T-62 Dose 1, T-62 Dose 2, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Tucson, Arizona • Westlake Village, California • Bradenton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 8, 2026, 12:03 PM EDT
Completed Phase 2 Interventional

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

NCT01748877
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
NXN-462, Placebo
Drug
Lead sponsor
NeurAxon Inc.
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 8, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)

NCT00612105
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Retigabine, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 8, 2026, 12:03 PM EDT
Completed Early Phase 1 Interventional

3VM1001 Cream for the Treatment of Pain Associated With Post Herpetic Neuralgia (PHN)

NCT03421613
View directory record Official record
Conditions
Treatment of PHN
Interventions
3VM1001, Placebo
Drug · Other
Lead sponsor
CDA Research Group, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 8, 2026, 12:03 PM EDT